ClinicalTrials.gov
ClinicalTrials.gov Menu

IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients (IMPACT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00294515
Recruitment Status : Completed
First Posted : February 22, 2006
Results First Posted : July 5, 2010
Last Update Posted : March 29, 2018
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche

Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double (Participant, Investigator);   Primary Purpose: Treatment
Condition: Cytomegalovirus Infections
Intervention: Drug: Valganciclovir

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Valganciclovir up to 100 Days 900 mg valganciclovir orally daily for up to 100 days
Valganciclovir up to 200 Days 900 mg valganciclovir orally daily for up to 200 days

Participant Flow:   Overall Study
    Valganciclovir up to 100 Days   Valganciclovir up to 200 Days
STARTED   166 [1]   160 [1] 
COMPLETED   132   132 
NOT COMPLETED   34   28 
[1] Randomized



  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Valganciclovir up to 100 Days 900 mg valganciclovir orally daily for up to 100 days
Valganciclovir up to 200 Days 900 mg valganciclovir orally daily for up to 200 days
Total Total of all reporting groups

Baseline Measures
   Valganciclovir up to 100 Days   Valganciclovir up to 200 Days   Total 
Overall Participants Analyzed 
[Units: Participants]
 164   156   320 
Age [1] 
[Units: Years]
Mean (Standard Deviation)
 48.5  (13.76)   47.0  (13.51)   47.8  (13.64) 
[1] Safety population
Sex: Female, Male [1] 
[Units: Participants]
Count of Participants
     
Female      45  27.4%      40  25.6%      85  26.6% 
Male      119  72.6%      116  74.4%      235  73.4% 
[1] Safety population


  Outcome Measures

1.  Primary:   Percentage of Patients Who Developed Cytomegalovirus (CMV) Disease up to Month 12 Post-transplant   [ Time Frame: 12 months post-transplant ]

2.  Secondary:   Percentage of Patients Who Developed CMV Disease up to Month 6 Post-transplant   [ Time Frame: 6 months post-transplant ]

3.  Secondary:   Percentage of Patients Who Developed CMV Disease up to Month 9 Post-transplant   [ Time Frame: 9 months post-transplant ]

4.  Secondary:   Percentage of Patients Who Developed CMV Disease up to Month 18 Post-transplant   [ Time Frame: 18 months post-transplant ]

5.  Secondary:   Percentage of Patients Who Developed CMV Disease up to Month 24 Post-transplant   [ Time Frame: 24 months post-transplant ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Medical Communications
Organization: Hoffmann-La Roche
phone: 800-821-8590


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT00294515     History of Changes
Other Study ID Numbers: NT18435
First Submitted: February 21, 2006
First Posted: February 22, 2006
Results First Submitted: June 2, 2010
Results First Posted: July 5, 2010
Last Update Posted: March 29, 2018